Adipotide (FTPP): Evidence, Mechanism, Dosing & Legal Status

Adipotide, also called the fat-targeted proapoptotic peptide (FTPP) or Prohibitin-Targeting Peptide-1, is a synthetic peptidomimetic designed to reverse obesity by ablating the vasculature of white fat rather than by suppressing appetite.1 Its preclinical results are among the most striking in the weight-loss peptide space; its human record is a single terminated trial. This monograph separates the two.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Adipotide is not an FDA-approved drug; it is sold as a "research chemical not for human use," carries a documented kidney-toxicity signal, and is prohibited in sport. Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is adipotide and how does it work?

Adipotide is a chimeric peptidomimetic with the sequence CKGGRAKDC-GG-D(KLAKLAK)2, built from two functional modules joined by a glycine-glycine linker.3 The first module, a disulfide-cyclized 9-mer homing domain (CKGGRAKDC), was isolated by in vivo phage display — screening huge combinatorial peptide libraries in living obese mice and selecting peptides that lodge in fat-tissue blood vessels — and was found to bind prohibitin, a membrane protein abnormally abundant on the luminal surface of white-adipose-tissue (WAT) endothelial cells.1 Prohibitin thus acts as a vascular "ZIP code" for white fat.

The second module, the amphipathic D-amino-acid killing sequence D(KLAKLAK)2, is inert until the construct is internalized by the endothelial cell. Once inside, it disrupts the mitochondrial membrane and triggers programmed cell death (apoptosis) of the fat-feeding endothelium; the D-enantiomer confers protease resistance.13 Mechanistically this is a fundamentally different strategy from appetite-suppressing or lipolytic drugs: adipotide does not signal hunger, block absorption, or mobilize fat — it selectively kills the microvasculature of white fat, after which adipocytes are resorbed and the depot shrinks.1 Prohibitin sits in a trimolecular complex with annexin A2 and CD36 on WAT endothelium that governs fatty-acid transport, so adipotide both ablates the vessel and disrupts the machinery delivering fatty acids to adipocytes.3 A defining preclinical feature is target selectivity for obese tissue: lean mice and lean monkeys lost little or no weight at the same doses, consistent with the expansion of WAT vasculature in obesity.13

What is the evidence by indication?

There are no human efficacy trials of adipotide for weight loss. The entire efficacy case rests on two animal studies, graded C (preclinical), with any human-facing claim graded D.

In the proof-of-concept study, daily SC adipotide for about four weeks produced resorption of established white fat and ~30% body-weight reduction in obese mice, with normalization of metabolism and no detectable adverse effects at the doses used, while lean mice were largely unaffected.1 The pivotal primate work then tested spontaneously obese rhesus macaques at 0.43 mg/kg SC daily for 28 days: treated animals lost 7.4-14.7% of body weight (group average about 10.6%), with no change in untreated controls.3 DEXA scanning showed total body fat down 38.7% in treated animals versus 14.8% in controls, and MRI showed abdominal white-fat volume down 17.5% at end of treatment and 27.0% after a 28-day recovery — confirming the loss was genuine fat mass across three monkey species.3 In the same study adipotide significantly improved insulin sensitivity, with insulin area-under-the-curve falling about 36% in treated animals versus controls, attributed to the loss of metabolically active visceral fat.3

The only human study is the registry record itself. The first-in-man Phase 1, NCT01262664, enrolled obese men with metastatic castrate-resistant prostate cancer at MD Anderson Cancer Center starting in May 2012 at 0.03 mg/kg SC daily for 28 days, on the rationale that shrinking fat tissue might slow tumor growth.4 It was terminated "per PI's request" after enrolling only four patients, with no results ever posted.4 There is therefore no published human efficacy or safety outcome for any indication.

What doses appear in the literature?

Reported strictly as information, not a protocol, and no validated human dose exists. Adipotide has excellent subcutaneous but poor oral bioavailability in mice, so all animal and human dosing used daily subcutaneous injection.1 Obese mice received daily SC injection for about 28 days.1 Obese rhesus monkeys received 0.43 mg/kg SC once daily for 28 days, derived by body-surface-area scaling from rodent doses; renal changes appeared at or above 0.25 mg/kg, while no lethality was seen up to 100 mg/kg (about 133x the therapeutic dose) in cynomolgus safety studies.3 The terminated human Phase 1 started at 0.03 mg/kg SC once daily for 28 days, with a planned escalation that was never completed.4 Gray-market "research chemical" reconstitution-and-injection regimens circulating online have no clinical-trial basis, no validated human dosing, and ignore the documented renal dose-limiting toxicity — and because the kidney injury in animals was dose-dependent, casual self-dosing is especially hazardous.3

How safe is adipotide?

The central safety story is dose-limiting renal toxicity. Across all primate studies the kidney was the target organ: adipotide produced dose-dependent injury to the renal proximal tubule, manifesting as rising serum creatinine (slight-to-moderate at or above 0.25 mg/kg), glucosuria and proteinuria, increased urinary epithelial cells, and decreased serum phosphorus and potassium, with histology showing tubular degeneration, single-cell necrosis and regeneration.3 Notably, BUN did not rise in parallel with creatinine, and the authors suggested part of the creatinine signal may reflect competitive inhibition of tubular creatinine secretion rather than pure filtration loss.3 Critically, most renal changes reversed within about 28 days of stopping the drug in monkeys — the toxicity was described as relatively mild, predictable and reversible — but this was characterized in animals only, and the human renal threshold is unknown.3

Because the only human trial was terminated at four patients with no posted results, there is no published human adverse-event data, no human renal-safety threshold, no human pharmacokinetics, and no long-term human safety information.4 Mechanism-based concerns add caution: because the drug works by inducing apoptosis in vascular endothelium, plausible but untested risks include off-target endothelial damage, impaired wound healing and angiogenesis, and effects on any prohibitin-expressing tissue, while lost fat depots could be regained after cessation.3 On an extrapolated basis (no label exists), adipotide should be avoided by anyone with renal impairment or risk factors for kidney injury, in pregnancy and lactation, in pediatric use, and alongside other nephrotoxic drugs.3 Products sold online as research chemicals are of uncertain identity, purity and sterility, and self-administration bypasses the renal-safety monitoring the animal data show is essential.3

What is the FDA and WADA status in 2026?

Adipotide is not FDA-approved for any indication; there is no NDA, BLA or marketed product. An Investigational New Drug application was cleared by the FDA in early 2012, enabling the single Phase 1 trial, which was subsequently terminated.54 Adipotide has no USP monograph and is not a recognized compounding-category substance; it is sold online only as a research chemical labeled "for research use only / not for human use," outside the legitimate drug-supply chain, and compounded or research-grade peptides marketed for human use remain a focus of FDA enforcement.7

For athletes the picture is unambiguous. A non-approved investigational substance like adipotide falls under Section S0 (Non-Approved Substances) of the WADA Prohibited List — any substance not currently approved by a governmental regulatory health authority for human therapeutic use is prohibited at all times, with no Therapeutic Use Exemption available.6 Because adipotide has never been approved for human use anywhere, any WADA-tested athlete should treat it as banned without exception.6

Bottom line. Adipotide is a scientifically important, mechanistically novel preclinical molecule — it validated the idea that obesity can be reversed by selectively ablating the blood supply of white fat via the prohibitin vascular "ZIP code," and it produced genuinely dramatic, imaging-confirmed fat loss in obese mice and monkeys.13 What is proven (Grade C) is the mechanism and efficacy in animals; what is hyped is any suggestion this is a proven or safe human therapy — there is no completed human trial, no published human safety or efficacy data, and no validated human dose. The key uncertainty, and the reason development stalled, is dose-dependent kidney toxicity — reversible in monkeys, uncharacterized in humans. In 2026 adipotide is not FDA-approved, banned in sport under S0, and available only as an unapproved research chemical. For anyone outside a formal preclinical lab, it is best understood as an unproven, kidney-risky experimental compound, not a therapy.